Doravirine and Oxcarbazepine Extended-Release Tablets
Determining the interaction of Doravirine and Oxcarbazepine Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:OXcarbazepine may significantly reduce the blood levels of doravirine, which may make the medication less effective in treating HIV infection. Additionally, it may lead to development of viral resistance to this and various other HIV medications that are currently used for treatment. Doravirine should generally not be started until at least 4 weeks after discontinuing OXcarbazepine. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:CONTRAINDICATED: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme. When a single 100 mg dose of doravirine was administered with the potent CYP450 3A4 inducer rifampin (600 mg once daily) in 10 study subjects, doravirine peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (C24hr) decreased by an average of 57%, 88% and 97%, respectively, compared to doravirine administered alone. Reduced efficacy of doravirine may occur.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with potent CYP450 3A4 inducers is considered contraindicated. At least a 4-week cessation period is recommended prior to initiation of doravirine treatment.
- "Product Information. Pifeltro (doravirine)." Merck & Company Inc, Whitehouse Station, NJ.
Generic Name: oxcarbazepine
Brand name: Oxtellar XR, Trileptal
Synonyms: Oxcarbazepine, OXcarbazepine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Doravirine-Oxcarbazepine Oral Suspension
- Doravirine-Oxcarbazepine Suspension
- Doravirine-Oxcarbazepine Tablets
- Doravirine-Oxecta
- Doravirine-Oxilan
- Doravirine-Oxipor VHC
- Oxcarbazepine Extended-Release Tablets-Doravirine, lamivudine, and tenofovir
- Oxcarbazepine Extended-Release Tablets-Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
- Oxcarbazepine Extended-Release Tablets-Doribax
- Oxcarbazepine Extended-Release Tablets-Doripenem
- Oxcarbazepine Extended-Release Tablets-Doripenem Intravenous
- Oxcarbazepine Extended-Release Tablets-Dornase Alfa